 HealthLinx is an emerging biomarker and diagnostic company with an integrated platform in biomarker and bioactive peptide discovery platforms. Its core focus is on the development of novel blood based diagnostics for targeted diseases that have un-met market need. HealthLinx develops novel, non-invasive, serum-based, diagnostic products. The Ovarian Cancer Program has completed a phase II biomarker trial with the outcome being the development of the first generation ovarian cancer diagnostic, OvPlex™. The company released OvPlex™ in the Australian market in October 2008 through its distribution partner, ARL Pathology (now Healthscope), as an elective test.
|
Blog: 
